Navigation Links
Mindray Announces 2010 Fourth Quarter and Full Year Results
Date:2/28/2011

it was $115.3 million, a 13.0% increase from $102.0 million in the fourth quarter 2009. Non-GAAP gross profit in the fourth quarter was $116.5 million, a 12.4% increase from $103.7 million in the fourth quarter 2009. The consolidated gross margin for the fourth quarter 2010 was 54.7% compared to 54.0% in the fourth quarter 2009 and 58.8% in the third quarter 2010. Non-GAAP gross margin was 55.2% in the fourth quarter 2010 compared to 54.9% in the fourth quarter 2009 and 59.5% in the third quarter 2010.

Operating ExpensesSelling expenses for the fourth quarter 2010 were $41.9 million, or 19.9% of the total net revenues, compared to 17.5% in the fourth quarter 2009 and 18.0% in the third quarter 2010. Non-GAAP selling expenses for the fourth quarter 2010 were $40.6 million, or 19.2% of the total net revenues, compared to 16.9% in the fourth quarter 2009 and 17.2% in the third quarter 2010.

General and administrative expenses for the fourth quarter 2010 were $18.3 million, or 8.7% of the total net revenues, compared to 8.5% in the fourth quarter 2009 and 9.0% in the third quarter 2010. Non-GAAP general and administrative expenses for the fourth quarter 2010 were $18.0 million, or 8.5% of the total net revenues, compared to 8.1% in the fourth quarter 2009 and 8.8% in the third quarter 2010.

Research and development expenses for the fourth quarter 2010 were $16.8 million, or 7.9% of the total net revenues compared to 7.8% in the fourth quarter 2009 and 8.8% in the third quarter 2010. Non-GAAP research and development expenses for the fourth quarter 2010 were $16.2 million, or 7.7% of the total net revenues compared to 7.5% in the fourth quarter 2009 and 8.3% in the third quarter 2010.

Total share-based compensation expenses, which were allocated to cost of goods sold and related operating expenses, were $1.7 million in the fourth quarter 2010 compared to $2.0 million in the fourth quarter 2009 and $1.9 million in the third quarter 2010.


'/>"/>
SOURCE Mindray Medical International Limited
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Mindray Announces FDA 510(k) Clearance of Its A5 Anesthesia System
2. Mindray to Report Fourth Quarter and Full Year 2010 Financial Results on February 28, 2011
3. Mindray Receives its Largest Order of Patients Monitors in Canada
4. Mindray Medical to Exhibit at Arab Health 2011 in Dubai from January 24-27
5. Mindray Medical Announces Preliminary 2010 Operating Results
6. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
7. Mindray Medical Announces Shareholder Resolutions Adopted at 2010 Annual General Meeting
8. Mindray Medical to Exhibit at MEDICA 2010 in Dusseldorf, Germany from November 17- 20, 2010
9. Mindray Announces Third Quarter 2010 Financial Results
10. Mindray Medical Announces Participation in Upcoming Investor Conferences
11. Mindray to Report Third Quarter 2010 Financial Results on November 8, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... Conference on Thursday, May 30, 2013 at 8:40 a.m. ET ... live audio webcast of the presentation will be available on ... www.isispharm.com .  A replay will be available on the ...
(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...
(Date:5/23/2013)... , May 23, 2013   BioLife Solutions , ... proprietary clinical grade hypothermic storage and ... contract aseptic media manufacturer , today announced its ... Regenerative Medicine Congress 2013 this week in ... ) Dr. Aby J. Mathew, BioLife,s Senior ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3
... - Results Highlight the Potential of ... Algeta ASA (OSE: ALGETA), the ... BC1-04 study reported today it has completed its,comprehensive phase ... for bone metastases in patients with hormone-refractory,prostate cancer (HRPC). ...
... After eight weeks of treatment, RAD001 halted tumor growth ... with chemotherapy - Based on these promising data, Novartis ... advanced gastric cancer patients- Gastric cancer is the second ... of new cases occurring in East AsiaEAST HANOVER, N.J., ...
Cached Medicine Technology:Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 2Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 3Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 4Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 5Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 6RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 2RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 3RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 4RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 5RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 6
(Date:5/23/2013)... high-risk neuroblastoma a common tumor that forms in the ... drugs. A study published by Cell Press in the ... reveals a new genomic approach to screen for compounds ... to differentiate, or convert from immature cells to more ... identified a compound that causes neuroblastoma cells to differentiate, ...
(Date:5/23/2013)... 2013 Sika Sarnafil , the ... today announced Imperial Roof Systems of Iowa as the ... dedication to quality during the re-roofing of the SuperTarget ... a Sika Sarnafil Elite contractor and one of Target’s ... is committed to sustainable building practices and they are ...
(Date:5/23/2013)... 23, 2013 Diabetes is one of ... become a nuisance when patients are unfortunate enough to ... the National Diabetes Information Clearinghouse at http://goo.gl/QyhCz , ... risk of developing neuropathy which further shrivels the nervous ... such patients. Such nerve damage affects the whole body ...
(Date:5/23/2013)... May 23, 2013 Professional Insurance Plans, ... the nation to celebrate Fibromyalgia Education and Awareness Month. ... chiropractors across the country, the agency feels that it ... of this syndrome that affects an estimated 10 million ... Association , the definition of Fibromyalgia (FM) is, “a ...
(Date:5/23/2013)... 2013 Retül University , the ... announce the formation of a strategic educational partnership with ... to offer a bike industry first “Positioned for Speed” ... for time trial, road and triathlon bike fit. , ... bike fitters with a Retül University, F.I.S.T. or S.I.C.I ...
Breaking Medicine News(10 mins):Health News:New screening approach uncovers potential alternative drug therapies for neuroblastoma 2Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2Health News:Neuropathy Nerve Damage Can Now Be Reversed With Neuracel 2Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 2Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 3
... Mark,s Breathe Easy Tour, Inspires Those with Chronic Lung Disease to ... ... SAN DIEGO, July 24 SeQual Technologies Inc. (SeQual),announced today the ... the American Lung,Association of California and Seton Medical Center intended to ...
... PALO ALTO, Calif., July 24 Horizon Therapeutics, ... Timothy P.,Walbert has been named president, chief executive ... Horizon Therapeutics., "Tim has a long, proven ... the pain and arthritis areas," said George,Tidmarsh, M.D., ...
... Free Diabetes Education and Cholesterol ... Screenings to Race Spectators, INDIANAPOLIS, Ind., July ... and Polymer Technology Systems,Inc. as a partner in the recently announced ... as cholesterol,screenings at the IndyCar Series during the 2008 racing season., ...
... $0.51 from $0.38 in ... - Record diluted EPS increased 30.2 percent to $0.56 from $0.43 in, second-quarter 2007, excluding ... from the ... - Specialty revenues increased 32.6 percent to a record of nearly $2.0 ...
... Mass., July 24 Tepha, Inc., a developer ... resorbable polymers, announced,today that it has appointed John ... and Chief Operating Officer. Mr. Hartnett joins Tepha,following ... which he,progressed from field sales, to marketing management, ...
... BEIJING, July 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, ... a leading China-based,medical device company that develops, ... high intensity focused ultrasound tumor,therapy systems, today ... results for the first quarter ended June ...
Cached Medicine News:Health News:SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride 2Health News:SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride 3Health News:SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride 4Health News:Horizon Therapeutics Names Timothy P. Walbert as President and CEO 2Health News:Eli Lilly and Company and Vision Racing Sponsor Vision Wellness Tour at the IndyCar Series Across the Country 2Health News:Eli Lilly and Company and Vision Racing Sponsor Vision Wellness Tour at the IndyCar Series Across the Country 3Health News:Eli Lilly and Company and Vision Racing Sponsor Vision Wellness Tour at the IndyCar Series Across the Country 4Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 2Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 3Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 4Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 5Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 6Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 7Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 8Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 9Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 10Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 11Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 12Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 13Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 14Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 15Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 16Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 17Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 18Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 19Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 20Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 21Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 22Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 23Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 24Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 25Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 26Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 27Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 28Health News:Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance 29
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: